Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide.

Miller KP, Venkataraman G, Gocke CD, Batista DA, Borowitz MJ, Burns KH, Pratz K, Duffield AS.

Am J Clin Pathol. 2019 Oct 7;152(5):675-685. doi: 10.1093/ajcp/aqz087.

PMID:
31305869
2.

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.

Lokhandwala PM, Tseng LH, Rodriguez E, Zheng G, Pallavajjalla A, Gocke CD, Eshleman JR, Lin MT.

BMC Cancer. 2019 Jul 5;19(1):665. doi: 10.1186/s12885-019-5864-1.

3.

Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.

Tseng LH, De Marchi F, Pallavajjalla A, Rodriguez E, Xian R, Belchis D, Gocke CD, Eshleman JR, Illei P, Lin MT.

Am J Clin Pathol. 2019 Oct 7;152(5):570-581. doi: 10.1093/ajcp/aqz077.

PMID:
31264684
4.

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.

Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS.

Clin Cancer Res. 2019 Sep 15;25(18):5475-5484. doi: 10.1158/1078-0432.CCR-18-1881. Epub 2019 Jun 11.

PMID:
31186313
5.

Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.

Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, Weiss MJ, Velculescu VE, He J, Wolfgang CL, Eshleman JR.

Clin Cancer Res. 2019 Aug 15;25(16):4973-4984. doi: 10.1158/1078-0432.CCR-19-0197. Epub 2019 May 29.

PMID:
31142500
6.

Genetically Related Choriocarcinoma Developing 5 Yr After a Complete Hydatidiform Mole and Simulating a Cornual Ectopic Pregnancy.

Chau DB, Beavis AL, Ronnett BM, Jenson E, Gocke CD, Anderson J, Nickles Fader A, Stone R.

Int J Gynecol Pathol. 2019 Apr 24. doi: 10.1097/PGP.0000000000000607. [Epub ahead of print]

PMID:
31033803
7.

Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.

Romo CG, Palsgrove DN, Sivakumar A, Elledge CR, Kleinberg LR, Chaichana KL, Gocke CD, Rodriguez FJ, Holdhoff M.

Diagn Pathol. 2019 Feb 9;14(1):16. doi: 10.1186/s13000-019-0793-5. Review.

8.

Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, Weihe E, Anagnostou V, Scharpf RB, Velculescu VE, Husain H.

Cancer Res. 2019 Mar 15;79(6):1204-1213. doi: 10.1158/0008-5472.CAN-18-1082. Epub 2018 Dec 20.

9.

Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers.

De Marchi F, Haley L, Fryer H, Ibrahim J, Beierl K, Zheng G, Gocke CD, Eshleman JR, Belchis D, Illei P, Lin MT.

Arch Pathol Lab Med. 2019 Feb;143(2):174-182. doi: 10.5858/arpa.2017-0495-OA. Epub 2018 Sep 7.

PMID:
30485130
10.

Clinical validation of coexisting driver mutations in colorectal cancers.

Zheng G, Tseng LH, Haley L, Ibrahim J, Bynum J, Xian R, Gocke CD, Eshleman JR, Lin MT.

Hum Pathol. 2019 Apr;86:12-20. doi: 10.1016/j.humpath.2018.11.014. Epub 2018 Nov 24.

PMID:
30481508
11.

Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers.

De Marchi F, Haley L, Fryer H, Ibrahim J, Beierl K, Zheng G, Gocke CD, Eshleman JR, Belchis D, Illei P, Lin MT.

Arch Pathol Lab Med. 2018 Sep 7. doi: 10.5858/arpa.2018-0495-OA. [Epub ahead of print]

PMID:
30192171
12.

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Leuk Res. 2018 Sep;72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10. No abstract available.

PMID:
30118897
13.

The Evolution of Earned, Transparent, and Quantifiable Faculty Salary Compensation: The Johns Hopkins Pathology Experience.

Burns KH, Borowitz MJ, Carroll KC, Gocke CD, Hooper JE, Amukele T, Tobian AAR, Valentine A, Kahl R, Rodas-Eral V, Boitnott JK, Jackson JB, Sanfilippo F, Hruban RH.

Acad Pathol. 2018 Jun 11;5:2374289518777463. doi: 10.1177/2374289518777463. eCollection 2018 Jan-Dec.

14.

Validation Strategy for Ultrasensitive Mutation Detection.

Debeljak M, Noë M, Riel SL, Haley LM, Norris AL, Anderson DA, Adams EM, Suenaga M, Beierl KF, Lin MT, Goggins MG, Gocke CD, Eshleman JR.

Mol Diagn Ther. 2018 Oct;22(5):603-611. doi: 10.1007/s40291-018-0350-z.

PMID:
29974360
15.

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.

Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, Liu C, Xie Z, Carson AR, McClain V, Stenzel TT, Miller JE.

Blood Adv. 2018 Apr 24;2(8):825-831. doi: 10.1182/bloodadvances.2018015925.

16.

Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera.

Ware AD, Birkness J, Duffield AS, Gocke CD.

Virchows Arch. 2018 Jul;473(1):131-135. doi: 10.1007/s00428-018-2347-8. Epub 2018 Apr 2. No abstract available.

PMID:
29611054
17.

PD-L1 expression in inflammatory myofibroblastic tumors.

Cottrell TR, Duong AT, Gocke CD, Xu H, Ogurtsova A, Taube JM, Belchis DA.

Mod Pathol. 2018 Jul;31(7):1155-1163. doi: 10.1038/s41379-018-0034-6. Epub 2018 Feb 15.

18.

Clinical mutational profiling of 1006 lung cancers by next generation sequencing.

Illei PB, Belchis D, Tseng LH, Nguyen D, De Marchi F, Haley L, Riel S, Beierl K, Zheng G, Brahmer JR, Askin FB, Gocke CD, Eshleman JR, Forde PM, Lin MT.

Oncotarget. 2017 May 20;8(57):96684-96696. doi: 10.18632/oncotarget.18042. eCollection 2017 Nov 14.

19.

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Gocke CD, Gladstone DE.

Br J Haematol. 2018 Jan;180(1):7-8. doi: 10.1111/bjh.15015. Epub 2017 Dec 3. No abstract available.

PMID:
29205267
20.

The Utility of NKX2.2 and TLE1 Immunohistochemistry in the Differentiation of Ewing Sarcoma and Synovial Sarcoma.

Rooper LM, Sharma R, Gocke CD, Belchis DA.

Appl Immunohistochem Mol Morphol. 2019 Mar;27(3):174-179. doi: 10.1097/PAI.0000000000000573.

PMID:
28800015
21.

Erratum to: Managing the genomic revolution in cancer diagnostics.

Nguyen D, Gocke CD.

Virchows Arch. 2017 Aug;471(2):195-197. doi: 10.1007/s00428-017-2193-0. No abstract available.

PMID:
28766009
22.

Managing the genomic revolution in cancer diagnostics.

Nguyen D, Gocke CD.

Virchows Arch. 2017 Aug;471(2):175-194. doi: 10.1007/s00428-017-2175-2. Epub 2017 Jun 21. Review. Erratum in: Virchows Arch. 2017 Aug 1;:.

PMID:
28639053
23.

Detection of Chromosomal Translocation in Hematologic Malignancies by a Novel DNA-Based Looped Ligation Assay (LOLA).

Harada S, Sizzle E, Lin MT, Gocke CD.

Clin Chem. 2017 Jul;63(7):1278-1287. doi: 10.1373/clinchem.2016.270140. Epub 2017 May 17.

24.

Haplotype Counting for Sensitive Chimerism Testing: Potential for Early Leukemia Relapse Detection.

Debeljak M, Mocci E, Morrison MC, Pallavajjalla A, Beierl K, Amiel M, Noë M, Wood LD, Lin MT, Gocke CD, Klein AP, Fuchs EJ, Jones RJ, Eshleman JR.

J Mol Diagn. 2017 May;19(3):427-436. doi: 10.1016/j.jmoldx.2017.01.005.

25.

Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component.

Avigdor BE, Beierl K, Gocke CD, Zabransky DJ, Cravero K, Kyker-Snowman K, Button B, Chu D, Croessmann S, Cochran RL, Connolly RM, Park BH, Wheelan SJ, Cimino-Mathews A.

Clin Cancer Res. 2017 Aug 15;23(16):4875-4884. doi: 10.1158/1078-0432.CCR-17-0108. Epub 2017 Apr 19.

26.

Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones.

Osman A, Gocke CD, Gladstone DE.

Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):97-99. doi: 10.1016/j.clml.2016.11.008. Epub 2016 Nov 21.

PMID:
28041846
27.

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.

Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00046. Epub 2017 May 31.

28.

A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.

Lee J, Axilbund J, Dalton WB, Laheru D, Watkins S, Chu D, Cravero K, Button B, Kyker-Snowman K, Waters I, Gocke CD, Lauring J, Park BH.

J Natl Compr Canc Netw. 2016 Dec;14(12):1495-1498.

PMID:
27956534
29.

Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.

Lokhandwala PM, Riel SL, Haley L, Lu C, Chen Y, Silberstein J, Zhu Y, Zheng G, Lin MT, Gocke CD, Partin AW, Antonarakis ES, Luo J, Eshleman JR.

J Mol Diagn. 2017 Jan;19(1):115-125. doi: 10.1016/j.jmoldx.2016.08.003. Epub 2016 Dec 1.

PMID:
27916435
30.

A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia.

Braunstein EM, Li R, Sobreira N, Marosy B, Hetrick K, Doheny K, Gocke CD, Valle D, Brodsky RA, Cheng L.

Leukemia. 2016 Nov;30(11):2242-2245. doi: 10.1038/leu.2016.173. Epub 2016 Jun 15. No abstract available.

31.

Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived.

Crane GM, Samols MA, Morsberger LA, Yonescu R, Thiess ML, Batista DA, Ning Y, Burns KH, Vuica-Ross M, Borowitz MJ, Gocke CD, Ambinder RF, Duffield AS.

PLoS One. 2016 Sep 29;11(9):e0163559. doi: 10.1371/journal.pone.0163559. eCollection 2016.

32.

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.

Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark TA, Gocke CD, Jeter SC, Kennedy MR, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V, Park BH.

Clin Cancer Res. 2017 Jan 15;23(2):379-386. doi: 10.1158/1078-0432.CCR-16-1543. Epub 2016 Aug 3.

33.

Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.

Belchis DA, Tseng LH, Gniadek T, Haley L, Lokhandwala P, Illei P, Gocke CD, Forde P, Brahmer J, Askin FB, Eshleman JR, Lin MT.

Oncotarget. 2016 Jul 19;7(29):45237-45248. doi: 10.18632/oncotarget.9931.

34.

Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing.

Zheng G, Lin MT, Lokhandwala PM, Beierl K, Netto GJ, Gocke CD, Eshleman JR, McCarthy E, Illei PB.

Cancer Cytopathol. 2016 Oct;124(10):744-753. doi: 10.1002/cncy.21743. Epub 2016 Jun 10.

35.

Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.

Zheng G, Tsai H, Tseng LH, Illei P, Gocke CD, Eshleman JR, Netto G, Lin MT.

Am J Clin Pathol. 2016 May;145(5):696-702. doi: 10.1093/ajcp/aqw043.

36.

Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide.

Kanakry CG, Coffey DG, Towlerton AM, Vulic A, Storer BE, Chou J, Yeung CC, Gocke CD, Robins HS, O'Donnell PV, Luznik L, Warren EH.

JCI Insight. 2016;1(5). pii: e86252. Epub 2016 Apr 21.

37.

Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Iglehart BS, Batista DA, Gocke CD, Ning Y, Knaus HA, Jackson AM, Leffell MS, Luznik L, Gojo I.

Leukemia. 2016 Oct;30(10):2102-2106. doi: 10.1038/leu.2016.144. Epub 2016 May 23. No abstract available.

38.

Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.

Gondek LP, Zheng G, Ghiaur G, DeZern AE, Matsui W, Yegnasubramanian S, Lin MT, Levis M, Eshleman JR, Varadhan R, Tucker N, Jones R, Gocke CD.

Leukemia. 2016 Sep;30(9):1916-1920. doi: 10.1038/leu.2016.63. Epub 2016 Mar 15. No abstract available.

39.

Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes.

Gerber JM, Zeidner JF, Morse S, Blackford AL, Perkins B, Yanagisawa B, Zhang H, Morsberger L, Karp J, Ning Y, Gocke CD, Rosner GL, Smith BD, Jones RJ.

Haematologica. 2016 May;101(5):607-16. doi: 10.3324/haematol.2015.135194. Epub 2016 Jan 27.

40.

The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.

Chang E, Ganguly S, Rajkhowa T, Gocke CD, Levis M, Konig H.

Leukemia. 2016 May;30(5):1025-32. doi: 10.1038/leu.2015.346. Epub 2015 Dec 21.

41.

Mutational spectrum of intraepithelial neoplasia in pancreatic heterotopia.

Ma C, Gocke CD, Hruban RH, Belchis DA.

Hum Pathol. 2016 Feb;48:117-21. doi: 10.1016/j.humpath.2015.09.023. Epub 2015 Oct 9.

42.

NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.

Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM.

J Natl Compr Canc Netw. 2015 Nov;13(11):1337-46.

PMID:
26553764
43.

Mutational profiling of colorectal cancers with microsatellite instability.

Lin EI, Tseng LH, Gocke CD, Reil S, Le DT, Azad NS, Eshleman JR.

Oncotarget. 2015 Dec 8;6(39):42334-44. doi: 10.18632/oncotarget.5997.

44.

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.

Zheng G, Tseng LH, Chen G, Haley L, Illei P, Gocke CD, Eshleman JR, Lin MT.

BMC Cancer. 2015 Oct 24;15:779. doi: 10.1186/s12885-015-1811-y.

45.

A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.

Lin MT, Tseng LH, Dudley JC, Riel S, Tsai H, Zheng G, Pratz KW, Levis MJ, Gocke CD.

Mol Diagn Ther. 2015 Dec;19(6):409-17. doi: 10.1007/s40291-015-0170-3.

46.

Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool.

Carter J, Tseng LH, Zheng G, Dudley J, Illei P, Gocke CD, Eshleman JR, Lin MT.

Am J Clin Pathol. 2015 Oct;144(4):620-8. doi: 10.1309/AJCP85ATMJOZOUDJ.

PMID:
26386083
47.

Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma.

Nauen DW, Guajardo A, Haley L, Powell K, Burger PC, Gocke CD.

Converg Sci Phys Oncol. 2015 Sep;1(1). pii: 015001. doi: 10.1088/2057-1739/1/1/015001. Epub 2015 Jun 16.

48.

Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.

Haley L, Tseng LH, Zheng G, Dudley J, Anderson DA, Azad NS, Gocke CD, Eshleman JR, Lin MT.

Mod Pathol. 2015 Oct;28(10):1390-9. doi: 10.1038/modpathol.2015.86. Epub 2015 Jul 31.

49.

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

Kanakry JA, Gocke CD, Bolaños-Meade J, Gladstone DE, Swinnen LJ, Blackford AL, Fuchs EJ, Huff CA, Borrello I, Matsui WH, Brodsky RA, Rosner GL, Shanbhag S, Luznik L, Jones RJ, Ambinder RF, Kasamon YL.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2115-2122. doi: 10.1016/j.bbmt.2015.07.012. Epub 2015 Jul 14.

50.

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.

Supplemental Content

Loading ...
Support Center